v3.26.1
Condensed Statements of Income (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Product sales $ 7,186,113 $ 6,444,880 $ 17,543,408 $ 14,512,054
Costs of goods sold 4,748,891 3,626,956 10,448,742 8,340,158
Gross profit 2,437,222 2,817,924 7,094,666 6,171,896
Administrative expenses 1,271,909 720,418 2,409,586 1,343,260
Sales and marketing expenses 1,110,727 696,086 2,343,490 1,552,744
Product development expenses 119,652 [1] 831,858 437,340 1,588,705
Other operating income (2,000,000) [2] 0 (2,000,000) [2] 0
Operating expenses (income) 502,288 2,248,362 3,190,416 4,484,709
NET OPERATING INCOME (LOSS) 1,934,934 569,562 3,904,250 1,687,187
Other (expenses) income, net (54,328) (65,778) (69,515) 265,485
INCOME BEFORE INCOME TAXES 1,880,606 503,784 3,834,735 1,952,672
Income tax expense 45,950 1,904 58,472 3,809
NET INCOME $ 1,834,656 $ 501,880 $ 3,776,263 $ 1,948,863
Basic weighted average common shares outstanding (in shares) 9,064,785 9,031,282 9,055,433 9,006,082
Basic net income per share (in dollars per share) $ 0.2 $ 0.06 $ 0.42 $ 0.22
Diluted weighted average common shares outstanding (in shares) 9,189,326 9,031,282 9,127,006 9,006,082
Diluted net income per share (in dollars per share) $ 0.2 $ 0.06 $ 0.41 $ 0.22
[1] Includes a $0.1 million reversal of an annual regulatory sponsor fee that we were no longer required to obtain as a result of the decision to cease focus on Re-Tain®.
[2] Includes a $2.0 million settlement with a former contract manufacturer that compensated the Company for operating costs incurred in product development and contract performance related to the development of the Company’s Re-Tain® product. See Note 9 for additional discussion.